PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129009
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129009
Percutaneous Nephrolithotomy market size was valued at US$ 1,580.2 Million in 2025, expanding at a CAGR of 7.7% from 2026 to 2033.
Percutaneous nephrolithotomy (PCNL) is a minimal surgical process that helps to get rid of kidney stones, also called renal calculi. In this procedure, a small opening is made in the skin, through which various instruments are used to disintegrate the stones and provide access to the kidney. Generally in those cases where other minimally invasive surgery techniques do not prove to be effective, such as lithotripsy using shock waves and ureteroscopy procedures, the PCNL technique becomes beneficial.
Three main kinds of PCNL are being employed, and these are, namely, the magnesium ammonium phosphate stone type, calcareous type, and uric acid calculus type. Main Components of Percutaneous Nephrolithotomy Accessories: The components, instruments and solutions that help in PCNL are procured by different hospitals, clinics and outpatient hospitals. Thus, the growing application of PCNL procedures has helped boost demand for stone removal devices and accessories.
Percutaneous Nephrolithotomy Market- Market Dynamics
Increasing prevalence of renal diseases to drive market expansion
The increasing prevalence of renal diseases is driving demand for percutaneous nephrolithotomy procedures, as there is the rising burden of stones in the kidneys and also of chronic kidney diseases, which make it necessary for the development of a procedure for stone removal, and PCNL is an effective standard procedure for handling large and complex kidney stones. For instance, in 2026, according to the Australian Institute of Health and Welfare (Org), an estimated 2.7 million Australians aged 18 years and above were estimated to have chronic kidney disease (CKD), which is 14.2% of the adult population in 2026. The rates of prevalence over time increased from 14% to 11.1% and 9.8%. With age, the burden of the disease increases; for those who are aged 75 years and older, the prevalence of CKD is 44.6%, whereas, for people aged between 18 and 44 years, it is only 7.2%. This rising disease burden is expected to increase demand for PCNL procedures for effective renal stone management.
The Global Percutaneous Nephrolithotomy market is segmented on the basis of Product Type, Procedure Type, Patient, End Use, and Region.
The nephroscope segment is the key segment in the Percutaneous Nephrolithotomy market, as it is employed for use in PCNL, as it is used to help achieve viewing and visibility in the renal collecting system, which helps in the detection and removal of kidney stones and acts as an important driver in the market. In July 2026, OLYMPUS introduced the OES Pro Series of hybrid lens imaging percutaneous nephroscopes, which include the long working length and high-flow sheath technology, to aid in percutaneous nephroscopy and PCNL. These advanced nephroscopes enhance procedural efficiency, visualisation, and stone removal during minimally invasive treatments.
Percutaneous Nephrolithotomy Market- Geographical Insights
North America suffers from a high burden of kidney stones, which is related to obesity, high intake of sodium, inactive lifestyles, and consumption of animal protein and processed food. For instance, in July 2025, according to the National Kidney Foundation (Org), over 500,000 Americans go to hospitals every year due to kidney stones, and approximately 1 out of 10 (10%) of the population develops kidney stones in their lifetime. There has been a tremendous increase in the burden to about 10 people out of 100 (10%), compared to four out of 100 people (4%). It is estimated that 11% of men and 9% of women are estimated to have a stone annually. As indicated by the Kidney Foundation, 10 or more people in 100 will have more than one kidney stone at some point in their life" and 1/2 or 2 or more men and women will have one or more kidney stones. This growing and recurring disease burden is driving demand for PCNL procedures across North America.
The major companies working in the market of percutaneous nephrolithotomy have shifted their focus towards technology-based solutions that improve the accuracy and efficiency of the process. In addition to this, they are also trying to make their presence felt in the market through the use of nephroscopes, lithotripters, access kits and imaging systems. The major players in the market include Boston Scientific Corporation, Olympus Corporation, Cook Medical, Karl Storz SE & Co. KG, and Merit Medical Systems, all of whom are focusing on producing minimally invasive tools, digital endoscopy, and laser lithotripters. In March 2026, Boston Scientific Corporation was granted FDA approval for its Asurys(TM) Fluid Management System, an advanced irrigation management system for use in ureteroscopy, cystoscopy, percutaneous nephrolithotomy (PCNL), and BPH procedures. These advancements are expected to strengthen competition and accelerate innovation in the Percutaneous Nephrolithotomy market.
In March 2026, Dornier MedTech entered into a commercial alliance with Potent Medical, through which it has become the exclusive distributor of Holmium: YAG laser and Thulium fibre laser systems, which are used in urological procedures such as treating kidney stones in defined areas of Europe, the Americas, and the Asia-Pacific.
In September, 2025, Cook Medical strengthened its position in the urology category through a deal between Cook Medical and Vizient that helped in increased distribution of its range of urology products.